Anti-Human Amyloid-β (Aducanumab) (A480-GRP)

Amyloid-β (Aβ) is a peptide that accumulates in the brains of individuals with Alzheimer’s disease, forming plaques that are a hallmark of the condition. These plaques are believed to contribute to the neurodegenerative processes seen in Alzheimer’s by disrupting cell function and triggering inflammatory responses. Amyloid-β is derived from the amyloid precursor protein (APP) through enzymatic cleavage. The aggregation of Aβ into oligomers and fibrils is a key pathological feature of Alzheimer’s disease, making it a significant target for therapeutic interventions aimed at reducing or preventing plaque formation 1,21,2. Aducanumab is a human monoclonal antibody of the IgG1 isotype that specifically targets aggregated forms of amyloid-β. Developed by Biogen and Neurimmune, Aducanumab was designed to bind to amyloid plaques in the brain, facilitating their clearance by the immune system. Clinical studies have shown that Aducanumab can reduce amyloid plaque levels in patients with early Alzheimer’s disease, potentially slowing cognitive decline. The development of Aducanumab involved identifying antibodies from healthy elderly individuals who were cognitively normal, leveraging their immune response to create a therapeutic antibody2-4.